Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineReferences
- A pharmacologic overview of current and emerging anticoagulants.Cleve Clin J Med. 2005; 72: S2-S6
- Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation.Discov Med. 2012; 13: 445-450
- Anticoagulation in atrial fibrillation: a new era has begun.Hamostaseologie. 2012; 32 ([in German]): 37-39
- Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.Annu Rev Med. 2011; 62: 41-57
- Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved drugs.Discov Med. 2012; 13: 433-443
- The mechanism of action of rivaroxaban—an oral, direct factor Xa inhibitor–compared with other anticoagulants.Thromb Res. 2011; 127: 497-504
- Emergency hospitalizations for adverse drug events in older Americans.N Engl J Med. 2011; 365: 2002-2012
- Medication use leading to emergency department visits for adverse drug events in older adults.Ann Intern Med. 2007; 147: 755-765
- Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study.Stroke. 2011; 42: 2431-2435
- The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage.Arch Intern Med. 2004; 164: 880-884
- Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.Arch Intern Med. 2007; 167: 1414-1419
- Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012; 141: e152S-e184S
- Biochemical comparison of seven commercially available prothrombin complex concentrates.Int J Clin Pract. 2008; 62: 1614-1622
- Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.Circulation. 2013; 128: 1234-1243
Sarode R. Four-factor prothrombin complex concentrate versus plasma for urgent VKA reversal: what's new? Clin Lab Med, in press.
- Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.Circulation. 2011; 124: 1573-1579
- Use of prothrombin complex concentrates for urgent reversal of dabigatran in the emergency department.Haematologica. 2013; 98: e143-e144
- Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial.J Thromb Haemost. 2008; 6: 622-631
- Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?.Thromb Haemost. 2013; 111 (Availabe at:): 189-198
- Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model.J Thromb Haemost. 2012; 10: 1841-1848
- Partial reversal of dabigatran effect by a prothrombin complex concentrate in a model of thrombin generation (2012 ASH abstracts).Blood. 2012; 120: 3420
- Antidotal effects of non-specific reversal agents on anticoagulant-induced inhibition of thrombin generation (2013 ISTH abstracts).J Thromb Haemost. 2013; 11: 562-563
- Reversal of the antithrombotic action of rivaroxaban and dabigatran: a clinical study in healthy volunteers. (2012 ASH abstracts).Blood. 2012; 120: 2261
- Effects of rivaroxaban and dabigatran on hemostasis and reversion of their antithrombotic effects by different coagulation factors. Evidence raised from a clinical study in healthy volunteers (2013 ISTH abstracts).J Thromb Haemost. 2013; 11: 418-419
- Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.Stroke. 2011; 42: 3594-3599
- The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation (2011 ASH abstracts).Blood. 2011; 118: 2316
Herzog E, Kaspereit F, Krege W, et al. Pre-clinical safety aspects on the use of Beriplex P/N for reversal of Dabigatran anticoagulation [abstract P5-1]. Paper presented at: 57th Annual Meeting of the German Thrombosis and Haemostasis Research Society. Munich, Germany, February 20–23, 2013.
- Non-clinical safety and efficacy of prothrombin complex concentrates (PCC) for the reversal of dabigatran mediated anticoagulation (2013 ISTH abstracts).J Thromb Haemost. 2013; 11: 693
van Ryn J, Schurer J, Kink-Eiband M, et al. Successful reversal of dabigatran-induced bleeding by 3-factor coagulation concentrates in a rat tail bleeding model: lack of correlation with ex vivo markers of anticoagulation. Paper presented at: AHA Scientific Sessions and Resuscitation Science Symposium. Los Angeles, USA, November 3–5, 2012.
- Alterations induced by rivaroxaban on hemostasis can be reversed by different coagulation factor concentrates: in vitro experimental studies with steady and circulating human blood (2013 ISTH abstracts).J Thromb Haemost. 2013; 11: 953-954
- Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban.Stroke. 2013; 44: 771-778
- Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.Thromb Haemost. 2013; 110: 162-172
- Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban (2013 ISTH abstracts).J Thromb Haemost. 2013; 11: 167
- Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.PLoS One. 2013; 8: e78696
- Four-factor prothrombin complex concentrate (4-PCC) effectively reverses edoxaban induced bleeding in a rabbit model of acute injury (2013 ASH abstracts).Blood. 2013; 122: 1133
- Clinical review: prothrombin complex concentrates—evaluation of safety and thrombogenicity.Crit Care. 2011; 15: 201
- Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.J Thromb Haemost. 2013; 11: 756-760
- In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.Thromb Res. 2012; 129: e77-e82
- Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.J Thromb Haemost. 2012; 10: 1830-1840
- Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose.Transfusion. 2009; 49: 1171-1177
- Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.Anesthesiology. 2012; 116: 94-102
- Management consensus guidance for the use of rivaroxaban—an oral, direct factor Xa inhibitor.Thromb Haemost. 2012; 108: 876-886
- Anticoagulation in atrial fibrillation.Arrhythmia & Electrophysiology Review. 2012; 1: 12-16
- A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.Nat Med. 2013; 19: 446-451
van Ryn J, Litzenburger T, Waterman A, et al. An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in vitro and in vivo models [Abstract P-MO-166]. Paper presented at: 57th Annual Meeting of the International Society on Thrombosis and Haemostasis. Kyoto, Japan, July 23–28, 2011.
van Ryn J, Litzenburger T, Schurer J. Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment) [abstract 9928]. Paper presented at: American Heart Association Scientific Sessions and Resuscitation Science Symposium. Los Angeles, USA, November 3–7, 2012.
Article info
Publication history
Footnotes
Conflict of Interest Statements: Prof. Dr G. Dickneite is an employee of CSL Behring and owns CSL Behring stock.
Editorial assistance was provided by Alan Saltzman at Fishawack Communications Ltd, with a grant from CSL Behring, Marburg, Germany.
